Spero Therapeutics Inc logo

Spero Therapeutics Inc(SPRO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SPRO

11/13/2026: SPRO (1-star) is currently NOT-A-BUY. Pass it for now.

Spero Therapeutics is a clinical-stage biotechnology company focused on developing therapies for multi-drug resistant bacterial infections. Its primary investment story centers on the potential of its SPR206 program and a strategic licensing agreement with GSK for its tebipenem HBr asset. While the partnership provides some financial validation and stability, the company faces high risks, including the potential for clinical trial failure, significant cash burn, and the inherent difficulty of the antibiotic market. Spero is suitable primarily for high-risk, speculative investors looking for potential binary outcomes in biotech. Interested parties should monitor clinical trial progress and the company's ability to manage its cash runway without excessive dilution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-risk, high-reward binary outcomes typical of clinical-stage biotech.
Momentum investorMixed fitMomentum is strictly conditional on positive clinical data or new partnership announcements.
Value investorWeak fitThe lack of consistent earnings and dependency on speculative future cash flows makes it unsuitable for value strategies.
Dividend investorWeak fitThe company does not pay dividends and prioritizes capital preservation for R&D.
Low-risk investorWeak fitHigh volatility and the risk of clinical failure represent unacceptable risk for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is highly sensitive to binary clinical data outcomes and regulatory announcements.
Valuation riskHighValuations are highly speculative and depend on future drug approval success.
Competition risk (antibiotic development)Medium / highCrowded field of researchers and incumbents makes market penetration difficult.
Business qualityMediumCompany is pre-commercial, relying on partners for long-term commercial success.
Dividend incomeLow / noneNo cash is returned to shareholders; capital is fully reinvested in operations.
Execution riskHighSuccessful execution of complex clinical trials is the primary determinant of value.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 58.26M USD
Price to earnings Ratio -
1Y Target Price 5.33
Price to earnings Ratio -
1Y Target Price 5.33
Volume (30-day avg) 378.8K shares
Beta 1.56
52 Weeks Range 0.95 - 3.08
Updated Date 11/14/2026
52 Weeks Range 0.95 - 3.08
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -18.88%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SPRO receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SPRO has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+112.5%) and solid revenue growth (+24.3%) are partially offset by weak cash generation (FCF margin -21.2%).

Financial Health Rating

★★★★★
SPRO's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 84.8%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SPRO's strongest growth driver at +112.5% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+24.3%, solid) and free-cash-flow growth (+46.2%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 21.2% and approximately 80.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 22.59% supports management-shareholder alignment.

Top 5 Institutional Investors

GSK PLC 15.78%
Pfizer Inc 4.06%
Vanguard Capital Management, LLC 3.50%
Renaissance Technologies Corp 1.63%
Alphabet Inc 1.53%

Unit Economics (Per $1K Revenue)

★★★★★
SPRO generates approximately $1,000 of gross profit, $-0 of operating income, and $-212 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.95%

Quantitative Style Profile

★★★★★
SPRO has a high-quality, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Licensing & CollaborationsMilestone payments and royalties from partners such as GSK for drugs like tebipenem HBr.Revenue is not from standard sales but from payments earned when the company hits specific development goals with its partners.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9.50M
Price to Sales(TTM) 1.24
Enterprise Value 9.50M
Price to Sales(TTM) 1.24
Enterprise Value to Revenue 0.22
Enterprise Value to EBITDA 1.44
Shares Outstanding 58.26M
Shares Floating 47.14M
Shares Outstanding 58.26M
Shares Floating 47.14M
Percent Insiders 22.59
Percent Institutions 21.2

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.